Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

Jane C. Davies; Steve Cunningham; William T. Harris; Allen Lapey; Warren E. Regelmann; Gregory S. Sawicki; Kevin W Southern; Sarah Robertson; Yulia Green; Jon Cooke; Margaret Rosenfeld

doi:10.1016/s2213-2600(15)00545-7

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

著者: Jane C. Davies, Steve Cunningham, William T. Harris, Allen Lapey, Warren E. Regelmann, Gregory S. Sawicki, Kevin W Southern, Sarah Robertson, Yulia Green, Jon Cooke, Margaret Rosenfeld - The Lancet 2016 被引用: 345

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study | Litlas